Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences in interactions of SSRIs

K Brøsen1

  • 1Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Denmark.

International Clinical Psychopharmacology
|November 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans.

Clinical pharmacology and therapeutics·2017
Same author

Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.

Clinical pharmacology and therapeutics·2017
Same author

Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2017
Same author

Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.

Clinical pharmacology and therapeutics·2016
Same author

Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Probe depth matters in dermal microdialysis sampling of benzoic acid after topical application: an ex vivo study in human skin.

Skin pharmacology and physiology·2011
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Selective serotonin reuptake inhibitors (SSRIs) vary in their cytochrome P450 enzyme interactions. Understanding these drug metabolism differences is crucial for safe SSRI prescribing and avoiding adverse effects.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Biochemistry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
  • Their elimination involves the cytochrome P450 (CYP) enzyme system.
  • CYP enzymes are crucial for drug oxidation and elimination, with over 30 identified in humans.

Purpose of the Study:

  • To investigate the differential inhibition of cytochrome P450 enzymes by various SSRIs.
  • To identify potential pharmacokinetic interactions between SSRIs and other drugs metabolized by CYP enzymes.
  • To highlight the clinical significance of these interactions for patient safety.

Main Methods:

  • Comparative analysis of SSRI chemical structures and pharmacokinetic profiles.
  • In vitro assessment of SSRI inhibition potential against specific CYP isoforms (CYP1A2, CYP2C19, CYP2D6, CYP3A4).

Related Experiment Videos

  • Review of known drug-drug interactions involving SSRIs and CYP substrates.

    • Main Results:

    • Fluvoxamine potently inhibits CYP1A2, leading to interactions with drugs like caffeine and clozapine.
    • Citalopram elimination is impaired in individuals with CYP2C19 deficiency (poor metabolizers).
    • SSRIs, particularly fluoxetine and paroxetine, are potent inhibitors of CYP2D6, affecting numerous drugs including tricyclic antidepressants.

    Conclusions:

    • SSRIs exhibit distinct patterns of CYP enzyme inhibition, influencing their pharmacokinetic interactions.
    • Clinicians must consider individual SSRI-CYP profiles to minimize risks of drug-drug interactions.
    • Awareness of these metabolic pathways is essential for optimizing SSRI therapy and patient outcomes.